Respreeza® Self-administration and Learning Program (AmAREtTI Study)
Key facts
- Who runs it
- CSL Behring
- Where
- France11 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 15 people enrolled
- Started
- 18 Oct 2019
- Ended
- 6 May 2024
- Type of study
- Observational
- Record updated
- 28 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult patients (age ≥18 years old)
- Patients suffering from AATD treated by Respreeza® through a peripheral vein at home for at least 3 month (consecutives or not). The 3-month period of treatment with Respreeza® does not necessarily correspond to the 3 months prior to inclusion
- Patient accompanied by a third person at home
- Patients deemed to be suitable by the investigator for self-administration
- Patients with a life expectancy of over 3 years
- Patients who have been informed verbally and in writing via the information leaflet and who have signed the informed consent form
Who cannot take part
- In order to reflect the reality of everyday practice, no non-inclusion criteria are intended except for patient refusal to take part in the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions may be administered at home by the person responsible for care or by the patient.
Read full original descriptionShow less
Clinical data on self-administration of Respreeza® are however limited and the grounds for self-administration are left to the assessment of the attending physician, who needs to ensure that appropriate training is delivered.
In this context, CSL Behring would like to run a clinical study in order to assess the effectiveness of a home self-administration learning program in terms of switching to self-administration, and the long term maintenance of this administration.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)
- Record updated
- 28 May 2025